Prognostic Value of IL-6 and VEGF in Metastatic Breast Cancer
Author Information
Author(s): Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay J-Y
Primary Institution: Unité Cytokine et Cancer, INSERM U-453 and Centre Léon Bérard, Lyon, France
Hypothesis
The study investigates the relationship between serum levels of IL-6 and VEGF and their potential relation to clinical outcomes in metastatic breast cancer patients.
Conclusion
High serum IL-6 levels are independently correlated with poor survival in metastatic breast cancer patients, while serum and plasma VEGF levels do not significantly correlate with survival.
Supporting Evidence
- High serum IL-6 levels were associated with a median survival time of 4 months.
- Patients with serum IL-6 levels below 13 pg/ml had a median survival time of 13 months.
- No correlation was found between survival and serum or plasma VEGF levels.
Takeaway
This study found that high levels of a substance called IL-6 in the blood can mean that breast cancer patients might not live as long, while another substance, VEGF, doesn't seem to help predict how long they will live.
Methodology
Serum and plasma samples were collected from patients, and levels of IL-6 and VEGF were measured using immunoassay kits.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific selection criteria for patients.
Limitations
The study's findings may not be generalizable due to the specific patient population and the low detection rate of IL-6.
Participant Demographics
Median age of participants was 54 years, with a range from 26 to 86 years; 47% had received adjuvant chemotherapy.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% confidence interval of HR 1.2–3.8
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website